News & Updates
Filter by Specialty:
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverage
Clinical outcomes within 1 year of MR-guided stereotactic body radiation therapy (MRgSBRT) with rectal spacer for patients with localized prostate cancer (PC) show excellent tolerability, minimal gastrointestinal (GI) toxicity as well as improved rectal sparing and target coverage vs a non-spacer comparison cohort.
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverage
20 Mar 2024
Men with HR+ breast cancer have high breast cancer─specific mortality risk at 20 years
Breast cancer–specific mortality (BCSM) risk remains high over 20 years in men with stage I─III hormone receptor (HR)–positive breast cancer and the kinetics are different from those seen in women, a population-based study has shown.
